ADMA Biologics Inc Shares Outstanding 2013-2024 | ADMA

ADMA Biologics Inc shares outstanding for the quarter ending September 30, 2024 were 0.245B, a 4.72% increase year-over-year.

  • ADMA Biologics Inc 2023 shares outstanding were 0.224B, a 13.19% increase from 2022.
  • ADMA Biologics Inc 2022 shares outstanding were 0.198B, a 41.77% increase from 2021.
  • ADMA Biologics Inc 2021 shares outstanding were 0.14B, a 62.03% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

ADMA Biologics Inc Shares Outstanding 2013-2024 | ADMA

  • ADMA Biologics Inc 2023 shares outstanding were 0.224B, a 13.19% increase from 2022.
  • ADMA Biologics Inc 2022 shares outstanding were 0.198B, a 41.77% increase from 2021.
  • ADMA Biologics Inc 2021 shares outstanding were 0.14B, a 62.03% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.8B
Vertex Pharmaceuticals (VRTX)$133.1B
Gilead Sciences (GILD)$120.2B
Bristol Myers Squibb (BMY)$109.8B
Regeneron Pharmaceuticals (REGN)$91B
CSL (CSLLY)$90.5B
GSK (GSK)$75.2B
Alnylam Pharmaceuticals (ALNY)$35.8B
Argenex SE (ARGX)$35.6B
BioNTech SE (BNTX)$26.3B
Biogen (BIIB)$25.2B
Illumina (ILMN)$24B
BeiGene (BGNE)$20B
Moderna (MRNA)$18B
Incyte (INCY)$16.1B
Genmab (GMAB)$15.3B
Vaxcyte (PCVX)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.6B
Exelixis (EXEL)$10.4B
Revolution Medicines (RVMD)$10.2B
QIAGEN (QGEN)$10B
Intra-Cellular Therapies (ITCI)$9.7B
Exact Sciences (EXAS)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$7.9B
Halozyme Therapeutics (HALO)$7.8B